MedTrace Logo

Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis

NCT01535027 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2013-01-03

No results posted yet for this study

Summary

Increased bone formation in the absence of accelerated resorption is resulting in a marked anabolic response to teriparatide (TPTD) during the early phase after treatment initiation. Months later, due to coupling mechanism, the sustained increase of bone formation and ongoing anabolic effects are accompanied by significantly increased bone resorption as well. Antiresorptives influence the balance of bone formation and resorption. Therefore the investigators aim is to investigate the effects of the addition of antiresorptives to the second half of TPTD cycle when resorption is already also markedly elevated.

Conditions

Interventions

DRUG

teriparatide

teriparatide 20 ug/day, sc.

DRUG

teriparatide and raloxifene

teriparatide 20 ug/day sc. raloxifene 60mg oral daily

DRUG

teriparatide and alendronate

teriparatide 20 ug/day sc. alendronate 70mg oral weekly

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Christian Muschitz, M.D. · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
88 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01535027 on ClinicalTrials.gov